Docetaxel-albumin–conjugates: preparation, in vitro evaluation and biodistribution studies

• In: G20 - Short oral communications on Pharmaceutical Manufacturing and Drug Delivery Technologies on Wednesday, 3 September 2008, 9:00-11:49
• At: Basel (Switzerland) (2008)
• Type: Presentation
• By: ESMAEILI, Farnaz (Tehran university of medical sciences, Tehran, Iran)
• Co-author(s): Sepehri, nima (Tehran university of medical sciences, Tehran, Iran)
  Rouhani, hasti (Tehran university of medical sciences, Tehran, Iran)
  Amini, mohsen (Tehran university of medical sciences, TEHRAN, Iran)
  Atyabi, fatemeh (Tehran university of medical sciences, Tehran, Iran)
  Ghahremani, Mohammad Hossein (Tehran university of medical sciences, Tehran, Iran)
  Dinarvand, Rassoul (Tehran university of medical sciences, Tehran, Iran)
  Ostad, Nasser (Tehran university of medical sciences, Tehran, Iran)
  
• Abstract:

  Docetaxel is one of the most active chemotherapeutic agents for treating metastatic breast cancer. Its aqueous solubility is very low, hence the available formulation of docetaxel for clinical use consists high concentrations of tween80 which has been associated with several hypersensitivity reactions. To reduce the systemic toxicity of docetaxel

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login